Alector - About the company
Alector is a public company based in San Francisco (United States), founded in 2013 by Asa Abeliovich and Arnon Rosenthal. It operates as a Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. Alector has raised $215M in funding from investors like AbbVie, Amgen Business Development and The Dementia Discovery Fund. The company has 513 active competitors, including 185 funded and 99 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.
Company Details
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. The drug candidates include AL001 for dementia, AL101 for neurology, AL002, AL003, AL014 for Alzheimer's, and AL008 for oncology. The company has developed antibody drugs that engage key disease-altering and genetically validated neuro-immune targets.
Key Metrics
Founded Year
2013
Location
San Francisco, United States
Stage
Public
Total Funding
$215M in 6 rounds
Latest Funding Round
Ranked
8th among 513 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2025
Employee Count
139 as on Jun 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Alector
Alector is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ALECTOR, INC. CIN: 1653087 , United States, Active | Sep 18, 2017 | $10M - $50M (As on Dec 31, 2025) | - | - |
Alector Llc CIN: 462702363 , United States, Active | - | 238 (As on Dec 31, 2024) | - |
Alector's IPO details
Alector got listed on Feb 07, 2019.
Click here to take a look at Alector's IPO in detail
Sign up to download Alector's company profile
Alector's funding and investors
Alector has raised a total funding of $215M over 6 rounds. Its first funding round was on Oct 31, 2013. Its latest funding round was a Series E round on Jul 25, 2018 for $*****. 17 investors participated in its latest round. Alector has 22 institutional investors.
Here is the list of recent funding rounds of Alector:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 25, 2018 | 2729709 | Series E | 7976970 | 7195685 | 7338697 | 6393288 |
Oct 17, 2017 | 2167728 | Series D | 8642461 | 1383875 | 2796379 | 2395645 |
Sep 30, 2016 | 5848393 | Grant (prize money) | 4756172 | 9731852 | 6669136 |
Access funding benchmarks and valuations. Sign up today!View details of Alector's funding rounds and investors
Alector's founders and board of directors
Founder? Claim ProfileThe founders of Alector are Asa Abeliovich and Arnon Rosenthal.
Here are the details of Alector's key team members:
- Asa Abeliovich: Co-Founder of Alector and founder of 2 other companies, Leal Therapeutics and Prevail Therapeutics. Contact Info: 1 email address
- Arnon Rosenthal: Co-Founder & CEO of Alector and founder of 2 other companies, Annexon and Rinat Neurosciences. Contact Info: 1 email address
View details of Alector's Founder profiles and Board Members
Alector's employee count trend
Alector has 139 employees as of Jun 26. Here is Alector's employee count trend over the years:
Uncover Alector's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Alector's Competitors and alternates
Top competitors of Alector include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Alector, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 71/100 | |
3rd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th | AnaptysBio 2005, San Diego (United States), Public | Developer of immunology therapeutics for cancer and inflammatory diseases | $85.7M | 67/100 | |
6th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Developer of small molecule inhibitors targeting specific disease associated enzymes | $192M | 66/100 | |
7th | Imcheck Therapeutics 2015, Marseille (France), Acquired | Developer of immunotherapeutic antibodies for the treatment of multiple diseases | $185M | 66/100 | |
8th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 65/100 | |
9th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
10th |  Athira Pharma 2011, Seattle (United States), Public | Developer of drugs for neurodegenerative diseases | $121M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Alector's competitors? Click here to see the top ones
Alector's Investments and acquisitions
Alector has made no investments or acquisitions yet.
Reports related to Alector
Here is the latest report on Alector's sector:
News related to Alector
Filter this listMedia has covered Alector for a total of 9 events in the last 1 year, 3 of them have been about company updates and 3 about people movement.
•
Alector GAAP EPS of -$0.21 in-line, revenue of $3.32M beats by $1.61M (NASDAQ:ALEC)Seeking Alpha•Aug 06, 2026•Alector
•
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappointsBioSpace•Apr 30, 2026•GSK, Alector
•
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business OfficerGlobeNewswire•Dec 13, 2025•Alector
•
FLY Investors Have Opportunity to Lead Firefly Aerospace Inc. Securities Fraud LawsuitPR Newswire•Nov 14, 2025•Schall Law Firm, Firefly Aerospace, Robbins Geller Rudman & Dowd, Bronstein, Gewirtz & Grossman and 15 others
•
•
GSK Halts Dementia Study After Trial Results; Moves Ahead with InhalerShareprices•Oct 22, 2025•GSK, Alector
•
Alector Phase 3 Trial Results: FTD-GRN Treatment Fails to Slow ProgressionGlobeNewswire•Oct 22, 2025•Alector
•
Alector Announces Executive Leadership Changes: Neil Berkley Named Interim CFOBenzinga•Jun 14, 2025•Alector
•
5AM Venture Management LLC Invests $1.88 Million in Alector, Inc. (NASDAQ:ALEC)MarketBeat•May 04, 2025•5AM Ventures, Alector
•
Alector Completes Enrollment in Phase II Alzheimer's Treatment Trialclinicaltrialsarena.com•Apr 21, 2025•Alector
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Alector
Explore our recently published companies
- Blue Sky Music - Washington based, Unfunded company
- Jude Cole - Unfunded company
- Glee Gather - Karachi based, 2023 founded, Unfunded company
- GLG Puertas - Mexico based, Unfunded company
- Apolo Bass - Spain based, Unfunded company
- Handwriting Olympiad - Hyderabad based, Unfunded company
